Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy to follicular lymphoma. The study compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.
The abstract ‘OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY’ (Abstract: S206) was was presented at the EHA2022 Congress, 9-12 June 2022.
- What are the unmet needs in the first-line treatment of patients with follicular lymphoma? (00:30-01:50)
- Could you give us a brief overview of the GALLIUM study and its efficacy and safety findings? (01:50-06:13)
- What have we learned from the final analysis of the GALLIUM study? (06:13-07:22)
- Which patients are most likely to benefit from obinutuzumab and in whom is it contraindicated? (07:22-08:35)
Disclosures: William Townsend is on the advisory board for: BMS, Roche and Takeda, and has received honoraria/honorarium from: BMS, Gilead, Incyte, Roche and Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 27th Congress of the European Hematology Association (EHA)
